ARCT
Arcturus Therapeutics Holdings Inc

5,456
Mkt Cap
$206.56M
Volume
1.13M
52W High
$24.17
52W Low
$7.26
PE Ratio
-2.95
ARCT Fundamentals
Price
$7.27
Prev Close
$7.77
Open
$7.44
50D MA
$16.18
Beta
1.76
Avg. Volume
2.08M
EPS (Annual)
-$3.00
P/B
0.88
Rev/Employee
$786,301.14
Loading...
Loading...
News
all
press releases
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve research firms that are currently covering the stock, MarketBeat...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to "Hold"
Wall Street Zen upgraded shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·7h ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Price Target Lowered to $9.00 at Citigroup
Citigroup dropped their price target on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Thursday...
MarketBeat·2d ago
News Placeholder
Research Analysts Offer Predictions for ARCT FY2025 Earnings
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Arcturus Therapeutics in a...
MarketBeat·2d ago
News Placeholder
William Blair Has Optimistic Outlook of ARCT FY2025 Earnings
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Stock analysts at William Blair lifted their FY2025 earnings estimates for shares of Arcturus Therapeutics in a research report...
MarketBeat·2d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Given New $72.00 Price Target at Piper Sandler
Piper Sandler decreased their target price on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an "overweight" rating on the stock in a report on Tuesday...
MarketBeat·4d ago
News Placeholder
HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $9.00
HC Wainwright decreased their price objective on Arcturus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday...
MarketBeat·4d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Issues Quarterly Earnings Results, Beats Estimates By $0.60 EPS
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating...
MarketBeat·5d ago
News Placeholder
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +60.80% and +50.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics...
Business Wire·6d ago

Latest ARCT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.